[
    [
        {
            "time": "",
            "orginal_text": "复锐医疗科技(01696)控股股东购买14.16万股公司股份",
            "features": {
                "keywords": [
                    "复锐医疗科技",
                    "控股股东",
                    "购买",
                    "股份"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "复锐医疗科技(01696)控股股东购买14.16万股公司股份",
            "scores": {
                "News_content": "复锐医疗科技(01696)控股股东购买14.16万股公司股份",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "开拓药业产品研发遇挫，另一家合作公司默沙东“中枪”",
            "features": {
                "keywords": [
                    "开拓药业",
                    "产品研发",
                    "遇挫",
                    "默沙东"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "开拓药业产品研发遇挫，另一家合作公司默沙东“中枪”",
            "scores": {
                "News_content": "开拓药业产品研发遇挫，另一家合作公司默沙东“中枪”",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "新浪医药年度盘点丨合久必分？2021医药行业十大拆分剥离动态 有人为“升级” 有人为“保命”",
            "features": {
                "keywords": [
                    "新浪医药",
                    "年度盘点",
                    "拆分剥离",
                    "升级",
                    "保命"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "新浪医药年度盘点丨合久必分？2021医药行业十大拆分剥离动态 有人为“升级” 有人为“保命”",
            "scores": {
                "News_content": "新浪医药年度盘点丨合久必分？2021医药行业十大拆分剥离动态 有人为“升级” 有人为“保命”",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 3,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "orginal_text": "复星医药(02196)：“18复药03”注销未转售债券金额9.91亿元",
            "features": {
                "keywords": [
                    "复星医药",
                    "18复药03",
                    "注销",
                    "债券"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "复星医药(02196)：“18复药03”注销未转售债券金额9.91亿元",
            "scores": {
                "News_content": "复星医药(02196)：“18复药03”注销未转售债券金额9.91亿元",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "复星医药(02196)：2021年度内董事变动后公司治理结构符合法律规定",
            "features": {
                "keywords": [
                    "复星医药",
                    "董事变动",
                    "治理结构",
                    "法律规定"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "复星医药(02196)：2021年度内董事变动后公司治理结构符合法律规定",
            "scores": {
                "News_content": "复星医药(02196)：2021年度内董事变动后公司治理结构符合法律规定",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "恒指收跌0.83%，恒生科技指数创历史低位",
            "features": {
                "keywords": [
                    "恒指",
                    "收跌",
                    "恒生科技指数",
                    "历史低位"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "恒指收跌0.83%，恒生科技指数创历史低位",
            "scores": {
                "News_content": "恒指收跌0.83%，恒生科技指数创历史低位",
                "Correlation": 3,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 10,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "上海复星医药集团：公司董事发生变动 董监高成员变化",
            "features": {
                "keywords": [
                    "上海复星医药集团",
                    "董事变动",
                    "董监高成员变化"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "上海复星医药集团：公司董事发生变动 董监高成员变化",
            "scores": {
                "News_content": "上海复星医药集团：公司董事发生变动 董监高成员变化",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "上海复星医药集团：“18复药03”完成转售",
            "features": {
                "keywords": [
                    "上海复星医药集团",
                    "18复药03",
                    "完成转售"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "上海复星医药集团：“18复药03”完成转售",
            "scores": {
                "News_content": "上海复星医药集团：“18复药03”完成转售",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "新冠“神药”临床结果未达预期，开拓药业否认失败，国内还有5款口服药在研",
            "features": {
                "keywords": [
                    "新冠",
                    "神药",
                    "临床结果",
                    "开拓药业",
                    "口服药"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "新冠“神药”临床结果未达预期，开拓药业否认失败，国内还有5款口服药在研",
            "scores": {
                "News_content": "新冠“神药”临床结果未达预期，开拓药业否认失败，国内还有5款口服药在研",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "港股异动 | 复星医药跌5% 子公司终止万格列净片药品临床试验及后续开发",
            "features": {
                "keywords": [
                    "港股",
                    "复星医药",
                    "子公司",
                    "终止",
                    "临床试验"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "港股异动 | 复星医药跌5% 子公司终止万格列净片药品临床试验及后续开发",
            "scores": {
                "News_content": "港股异动 | 复星医药跌5% 子公司终止万格列净片药品临床试验及后续开发",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "[港股通]复星医药(02196)跌逾4% 子公司终止药品临床试验",
            "features": {
                "keywords": [
                    "港股通",
                    "复星医药",
                    "子公司",
                    "终止",
                    "药品临床试验"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "[港股通]复星医药(02196)跌逾4% 子公司终止药品临床试验",
            "scores": {
                "News_content": "[港股通]复星医药(02196)跌逾4% 子公司终止药品临床试验",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]